Daniel Ory, M.D.

Daniel Ory, M.D.
Sr. Vice President of Translational Medicine

Dan Ory comes to Casma from Washington University School of Medicine in St. Louis, where he served as the Alan A. and Edith L. Wolff Professor of Cardiology and was a tenured professor of medicine, cell biology and physiology. Dan has an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed his residency at Brigham and Women’s Hospital and his fellowship in the cardiac unit at Massachusetts General Hospital. He performed his postdoctoral training at the Whitehead Institute at the Massachusetts Institute of Technology.

Over the past two decades, his laboratory has made fundamental contributions to our understanding of cholesterol biology and Niemann-Pick disease type C (NPC), a rare genetic neurodegenerative disease. He is internationally recognized for this research and has co-authored over 120 peer-reviewed publications. These efforts have resulted in the development of new diagnostic NPC biomarkers. Clinical assays based on these biomarkers have transformed the way in which NPC is diagnosed and have been implemented worldwide. A newborn screen for NPC developed by his lab is now being piloted in state labs. Working closely with the NIH, Dan led development of the Phase 1/2a trial of intrathecal cyclodextrin and was instrumental in the recruitment of a pharmaceutical partner to conduct the international, multisite Phase 2/3 trial.

Dan is a valued consultant in the scientific community. He has served on numerous scientific advisory boards, including those of the National Niemann-Pick Disease Foundation, Stride Bio Scientific, and the Ara Parseghian Medical Research Foundation. Dan is also a champion of rare disease research and has been honored many times for his work. Most recently, he received the Global Genes RARE Champion of Hope Award in 2016. The following year, he was honored with the Harrington Scholar-Innovator award, which recognizes researchers who have the potential to change the standard of care for patients.

Why Casma, Why Me?

I am excited by the Casma team’s determination to harness autophagy to treat disease and inspired by their passion to change patients’ lives. I am proud to be directing my experience in drug development in rare genetic disease toward this important goal.